Biotech Values

[DewDiligence]

There will always be better drugs at earlier stages but I figure Roche has the bucks to spend to take what they have and know well forward and see if there is still a tox signal or not (at the lower dose boosted with ritonavir).

Ritonavir boosting is not the solution—it’s the problem. This is what I’ve been saying all along, and Dan Welch finally acknowledged it on ITMN’s CC on Oct 6.